Elucid Launches First of Its Kind PlaqueIQ™ for Advanced Carotid Artery Plaque Analysis

Elucid, an AI-driven medical technology company specialising in atherosclerosis imaging, has announced the launch of PlaqueIQ™, its new image analysis software for the quantification and classification of plaque morphology in the carotid arteries. 

PlaqueIQ is the first and only CT-based plaque analysis software cleared by the U.S. Food and Drug Administration (FDA) for use in the carotid vasculature. 

It is designed to help clinicians identify high-risk carotid plaques and guide personalised treatment strategies to prevent ischaemic stroke.

PlaqueIQ provides non-invasive CT Virtual Histology™, offering an objective, histology-based analysis of plaque composition. 

The software can identify and quantify lipid-rich necrotic core—an indicator strongly associated with both cardiovascular and cerebrovascular risk. 

This allows for a more accurate assessment of stroke risk compared with traditional stenosis-based evaluation methods.

By analysing both coronary and carotid arteries, PlaqueIQ enables a comprehensive evaluation of systemic atherosclerotic risk within a single CT scan. 

The technology supports physicians in tailoring treatment plans according to individual plaque characteristics, helping to improve decision-making, monitor disease progression, and reduce the likelihood of heart attack and stroke.

Elucid states that PlaqueIQ represents a major step towards personalised, image-guided cardiovascular and cerebrovascular care.